MNKD · MannKind Corporation
$4.13
-1.01% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
18.2
Dividend yield
—
Beta
1.09
Avg volume
6M
Employees
1K
2D change
—
5D change
1.54%
10D change
-1.99%
30D change
-4.59%
60D change
4.77%
MTD change
-2.47%
YTD change
-30.34%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MNKD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-07
Latest call per bank · past 12 months
RBC Capital
Sector Perform$4.75
+15.0% vs priceWells Fargo
Overweight$10.00
+142.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-07 | RBC Capital | Maintains | Sector Perform | $3.50 → $4.75 |
| 2026-05-07 | Wells Fargo | Maintains | Overweight | $8.00 → $10.00 |
| 2026-05-07 | Mizuho | Maintains | Outperform | $8.00 → $7.00 |
| 2026-05-07 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10.00 |
| 2026-04-28 | Wells Fargo | Maintains | Overweight | $7.00 → $8.00 |
| 2026-04-13 | Mizuho | Maintains | Outperform | $10.00 → $8.00 |
| 2026-03-05 | Wedbush | Maintains | Outperform | $10.00 → $8.00 |
| 2026-02-27 | RBC Capital | Downgrade | Outperform → Sector Perform | $7.50 → $3.50 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.9% above the 50-day MA ($3.80).
- Price vs 200-day MA: Trading 10.1% below the 200-day MA ($4.35).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.04) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.28) and high ($6.21).
MNKD Price Chart
Loading chart for MNKD…
Fundamentals
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.